MedicalResearch.com Interview with: [caption id="attachment_61115" align="alignleft" width="125"] Prof. Nathan Berger[/caption] Nathan A. Berger, M.D. Distinguished University Professor
Hanna-Payne Professor of Experimental Medicine
Professor of Medicine, Biochemistry, Oncology and Genetics
Director, Center for Science, Health and Society
Case Western Reserve University School of Medicine   [caption id="attachment_61116" align="alignleft" width="125"] Prof. Rong Xu[/caption] Rong Xu, PhD Professor, Biomedical Informatics Director, Center for Artificial Intelligence in Drug Discovery Case Western Reserve University School of Medicine     MedicalResearch.com: What is the background for this study? Response: 75% of the US Population has overweight or obesity and 15% has Type 2 Diabetes. Both overweight/obesity and diabetes promote increased incidence and worse prognosis of colorectal cancer. The new GLP1RA drug class are rapidly becoming the most effective treatment for both diabetes and overweight/obesity. By controlling diabetes and overweight/obesity, we hypothesized that the GLP1RAs might be effective at reducing incidence of colorectal cancer.